Dana-Farber's Center for Immuno-Oncology (CIO) conducts clinical studies in one of the most exciting areas of cancer research today: unleashing the power of the body’s immune system to detect and combat tumors.
The Joint Center for Cancer Precision Medicine has been established to create "precision medicine treatment pathways" for patients with advanced cancers and to speed the development of personalized therapies.
The human immune system is capable of recognizing cancer cells, but it doesn't effectively kill them: Dana-Farber discoveries show why this is so, and how drugs can be developed to overcome this immune suppression.
Our mission is to facilitate the transfer of research innovations from the laboratory to the clinic through timely commercialization, and to help Dana-Farber investigators create these innovations through external collaborations and relationships with industry. Read more
Cancer Immunotherapy: Blocking the PD-1/PD-L1 Checkpoint
Dana-Farber has licensed a large patent portfolio covering PD-1 and PD-L1 to multiple pharmaceutical companies.
Evotec: Dana-Farber's Belfer Institute Collaboration
A partnership between Evotec and the Belfer Institute is aimed at discovering and commercializing novel cancer treatments based on epigenetic drug mechanisms.
Aileron Therapeutics and Stapled Peptides
Dana-Farber has licensed a stapled peptide patent portfolio to Aileron enabling a breakthrough approach to creating drugs using this novel peptide stabilizing technology.
Tensha Therapeutics and Bromodomain Inhibition
A potent small molecule BET bromodomain inhibitor from the laboratory of Dana-Farber’s James Bradner, MD, licensed to Tensha Therapeutics, has entered clinical trials.
O. Prem Das, PhD, Chief Research Business Development OfficerGary Sclar, JD, Associate Director
For general questions: firstname.lastname@example.orgFor Academic MTAs: email@example.com
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: